Urinary osteoprotegerin: a potential biomarker of lupus nephritis disease activity

被引:14
|
作者
Gupta, R. [1 ]
Aggarwal, A. [1 ]
Sinha, S. [2 ]
Rajasekhar, L. [3 ]
Yadav, A. [1 ]
Gaur, P. [1 ]
Misra, R. [1 ]
Negi, V. S. [4 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Clin Immunol, C Block,Rae Bareli Rd, Lucknow 226014, Uttar Pradesh, India
[2] Cent Drug Res Inst, Div Biochem, CSIR, Lucknow, Uttar Pradesh, India
[3] Nizam Inst Med Sci, Dept Rheumatol, Hyderabad, Andhra Pradesh, India
[4] JIPMER, Dept Clin Immunol, Pondicherry, India
关键词
SLE; lupus nephritis; biomarker; urinary; osteoprotegerin; ENDOTHELIAL-CELLS;
D O I
10.1177/0961203316636470
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Urinary biomarkers may help in identification, treatment and assessment of response in patients with lupus nephritis (LN). Osteoprotegerin (OPG) is produced by the kidneys and lymphoid cells and may reflect renal disease activity better. The data on its utility are sparse. Methods Fifty-eight patients with active LN (AN), 24 with active non-renal disease (ANR) and 39 with inactive disease (ID) were included. Median disease duration was 32 (1-204) months and median age was 27 (12-50) years. AN patients were followed up every three months for one year. Urine and serum samples were collected for OPG measurement by ELISA (pg/ml) and urinary values were normalised for creatinine excretion (pg/mg). Urine samples from 24 healthy individuals (HCs) and 20 patients each of rheumatoid arthritis (RA) and diabetic nephropathy (DM) served as controls. Variables were expressed as median (range). Results At baseline, normalised urinary OPG (uOPG) was significantly higher (p<0.001) in AN (1229 (0-8577)) than ANR (236 (0-14713)), ID (463 (7-4253)), HCs (366 (120-2849)) and DM (350 (127-1577)) but it was not different from RA (1511 (122-8849)). uOPG correlated modestly with rSLEDAI (r=0.4, p<0.001) and SLEDAI (r=0.31, p<0.001) but not with serum OPG (sOPG). uOPG but not sOPG could differentiate between AN and ANR groups. In the longitudinal study, uOPG and sOPG decreased significantly with treatment at all follow-up visits but the trend of fall in sOPG was erratic. uOPG values at baseline, 3, 6, 9 and 12 months were 1229 (0-8577), 466 (3-4874), 104 (0-1598), 325 (0-4025) and 555 (6-6771) pg/mg, respectively. uOPG but not sOPG rose before conventional markers in three patients who had a relapse of LN. In two patients who developed chronic kidney disease, uOPG remained persistently high. For differentiating AN from ANR patients, uOPG performed the best on receiver operator characteristics analysis (AUC=0.72) when compared with anti-dsDNA antibodies, C3, C4 and sOPG. Conclusion uOPG is derived from kidneys and helps differentiate active SLE patients with and without LN. It shows modest correlation with disease activity and has a potential to predict poor response to therapy and relapse of LN.
引用
收藏
页码:1230 / 1236
页数:7
相关论文
共 50 条
  • [21] URINARY LIPOCALIN-2 AS A BIOMARKER OF RENAL DISEASE ACTIVITY IN PATIENTS WITH LUPUS NEPHRITIS: A PROSPECTIVE STUDY
    Gamal, N. M.
    Mustafa, N. M.
    Abda, E. A. M.
    Afifi, O.
    Fathi, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 808 - 809
  • [22] URINARY SOLUBLE VCAM-1 IS A USEFUL BIOMARKER OF DISEASE ACTIVITY AND TREATMENT RESPONSE IN LUPUS NEPHRITIS
    Gasparin, A. A.
    Pamplona Bueno de Andrade, N.
    Hax, V.
    Palominos, P.
    Siebert, M.
    Marx, R.
    Shaefer, P.
    Verissimo Veronese, F.
    Monticielo, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1502 - 1503
  • [23] Urinary Galectin-3 Binding Protein As a Novel Biomarker of Renal Disease Activity in Lupus Nephritis
    Ding, Huihua
    Ling, Cheng
    Bassi, Roberto
    Okitsu, Shinji L.
    DeMartino, Julie A.
    Shen, Nan
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [24] Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis
    Gasparin, Andrese Aline
    Bueno de Andrade, Nicole Pamplona
    Hax, Vanessa
    Palominos, Penelope Esther
    Siebert, Marina
    Marx, Romulo
    Schaefer, Pedro Guilherme
    Veronese, Francisco Verissimo
    Monticielo, Odirlei Andre
    BMC RHEUMATOLOGY, 2020, 4 (01)
  • [25] Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity
    Turnier, Jessica L.
    Brunner, Hermine I.
    Bennett, Michael
    Aleed, Ashwaq
    Gulati, Gaurav
    Haffey, Wendy D.
    Thornton, Sherry
    Wagner, Michael
    Devarajan, Prasad
    Witte, David
    Greis, Kenneth D.
    Aronow, Bruce
    RHEUMATOLOGY, 2019, 58 (02) : 321 - 330
  • [26] URINARY HER2: A NEW BIOMARKER OF PEDIATRIC LUPUS NEPHRITIS ACTIVITY
    Costa-reis, Patricia
    Maurer, Kelly
    Petri, Michelle A.
    Burnham, Jon M.
    O'neil, Kathleen
    Klein-gitelman, Marisa
    Von Scheven, Emily
    Schanberg, Laura E.
    Sullivan, Kathleen E.
    PEDIATRIC NEPHROLOGY, 2022, 37 (11) : 2806 - 2806
  • [27] Urinary TWEAK/Fn14 mRNA as a biomarker of lupus nephritis activity
    Xu, Xiaoyan
    Zheng, Min
    Liu, Bicheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (06): : 11236 - 11243
  • [28] Urinary Angiotensinogen Predicts Renal Disease Activity in Lupus Nephritis
    Shi, Meng
    Luo, Weihong
    Feng, Xiaodan
    Jin, Lingwei
    Yang, Manqiu
    Wu, Liling
    Yang, Zhichen
    Su, Cailing
    Li, Yajing
    Su, Huanjuan
    Wang, Guobao
    Gao, Wei
    ANTIOXIDANTS & REDOX SIGNALING, 2019, 31 (17) : 1289 - 1301
  • [29] Urinary TWEAK and the activity of lupus nephritis
    Schwartz, Noa
    Su, Lihe
    Burkly, Linda C.
    Mackay, Meggan
    Aranow, Cynthia
    Kollaros, Maria
    Michaelson, Jennifer S.
    Rovin, Brad
    Putterman, Chaim
    JOURNAL OF AUTOIMMUNITY, 2006, 27 (04) : 242 - 250
  • [30] Urinary Biomarker to Predict Renal Outcomes in Lupus Nephritis
    Baker, Ryan
    Whittall-Garcia, Laura
    Kim, Michael
    Bonilla, Dennisse
    Urowitz, Murray
    Gladman, Dafna
    Touma, Zahi
    Wither, Joan
    JOURNAL OF RHEUMATOLOGY, 2024, 51 : 30 - 31